CD274 and hypothyroidism: The incidence of hyperthyroidism and hypothyroidism following anti-PD-L1 therapy is reported to be 0.7% and 3.8–5.5%, respectively, and multiple cases of thyroid disorder post-atezolizumab have been reported [32,33,34].